Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Sylvia C. van Buul-Offers"'
Autor:
Klas Blomgren, Sylvia C. van Buul-Offers, Floris Groenendaal, Cacha Peeters-Scholte, Nicole Kops, Kees P.J. Braun, Henrik Hagberg, Giuseppe Buonocore, Klaas Nicolay, J. G. Koster, Frank van Bel
Publikováno v:
Pediatric Research, 54(4), 516-522. Lippincott Williams and Wilkins Ltd.
The hypothesis was tested that treatment with allopurinol, a xanthine oxidase inhibitor, or deferoxamine, a chelator of nonprotein-bound iron, preserved cerebral energy metabolism, attenuated development of edema, and improved histologic outcome in t
Autor:
Harry Vermeer, Bart van der Burg, Brenda I. Hendriks-Stegeman, Maarten Jansen, Sylvia C. van Buul-Offers
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 88:277-284
To reduce the side effects of corticosteroid treatment, the administered dose of glucocorticoids (GCs) should be kept to a minimum while preserving therapeutically needed intracellular levels. Currently available assays to determine individual sensit
Autor:
Klaas Hoekman, Aart H. Mudde, J. G. Koster, Jaap van Doorn, Sylvia C. van Buul-Offers, R. J. Bloemen, Cok M. Hoogerbrugge
Publikováno v:
Clinical Chemistry. 48:1739-1750
Background: Detection of incompletely processed precursor forms of insulin-like growth factor-II (“big” IGF-II) in plasma is essential for both the diagnosis and follow-up of non-islet cell tumor-induced hypoglycemia (NICTH) and may be relevant t
Publikováno v:
Biochemical and Biophysical Research Communications. 240:707-714
Insulin-like growth factor binding proteins (IGFBPs) are important modulators of IGF actions. IGFBP-3 and IGFBP-5 can bind to the extracellular matrix of a number of cell types. We now describe a new posttranslational structural modification of IGFBP
Autor:
Jeske J. Smink, Ria Gresnigt, Sylvia C. van Buul-Offers, Marcel Karperien, JA Koedam, Nicole Hamers
Publikováno v:
Pediatric nephrology (Berlin, Germany). 20(3)
Growth retardation is a serious side effect of long-term glucocorticoid (GC) treatment. In order to prevent or diminish this deleterious effect, a combination therapy including growth hormone (GH), a stimulator of bone growth, is often recommended. P
Autor:
Wilson Savino, Vinicius Cotta-de-Almeida, Sylvia C. van Buul-Offers, J. G. Koster, Mireille Dardenne
Publikováno v:
Neuroimmunomodulation. 12(2)
Objectives: Intrathymic T cell differentiation is driven by the thymic microenvironment, a tridimensional network of cells and extracellular matrix (ECM). Previous data showed that lymphoid and microenvironmental compartments are under the control of
Autor:
Brenda I. Hendriks-Stegeman, Sylvia C. van Buul-Offers, Maarten Jansen, Denise van Suylekom, Harry Vermeer, Ger T. Rijkers
Publikováno v:
Molecular and cellular endocrinology. 218(1-2)
Individual variation in sensitivity to glucocorticoids (GCs) poses a dilemma to the clinician. Currently available assays to determine individual sensitivity to GCs either seem imprecise, or they are based on mitogen-activated lymphocytes, although m
Autor:
Ria Gresnigt, R. J. Bloemen, J. G. Koster, Gilliam Kuijpers, Sylvia C. van Buul-Offers, Raoul P. A. Rooman
Publikováno v:
Endocrinology
Endocrinology, 144(6), 2553-2558. ENDOCRINE SOC
Endocrinology, 144(6), 2553-2558. ENDOCRINE SOC
Supraphysiological doses of glucocorticoids cause growth retardation in both animals and humans. Many studies have addressed the interaction of glucocorticoids with the GH/IGF system, but little is known about the effect of glucocorticoids on T(4)-st
Publikováno v:
Molecular and cellular endocrinology. 197(1-2)
Vascular endothelial growth factor (VEGF) plays an essential role in angiogenesis in the growth plate and ultimately in regulating endochondral ossification. Since longitudinal bone growth is often disturbed in children who are treated with glucocort
Autor:
Jaap, van Doorn, Cok M, Hoogerbrugge, Johanna G, Koster, Ruud J, Bloemen, Klaas, Hoekman, Aart H, Mudde, Sylvia C, van Buul-Offers
Publikováno v:
Clinical chemistry. 48(10)
Detection of incompletely processed precursor forms of insulin-like growth factor-II ("big" IGF-II) in plasma is essential for both the diagnosis and follow-up of non-islet cell tumor-induced hypoglycemia (NICTH) and may be relevant to other diseases